Table 1 List of the 30 countries selected for the modelling analysis.

From: Modelling the global burden of drug-resistant tuberculosis avertable by a post-exposure vaccine

Countries having a strong private healthcare sector (i)

Countries where HIV is a driver of TB epidemiology (ii)

Countries with both a private sector and driving role of HIV in TB

All remaining countries

• India (IND)

• Pakistan (PAK)

• Indonesia (IDN)

• Philippines (PHL)

• Myanmar (MMR)

• Bangladesh (BGD)

• Ethiopia (ETH)

• Russia Federation (RUS)

• Ukraine (UKR)

• South Africa (ZAF)

• Mozambique (MOZ)

• DR Congo (COD)

• Zimbabwe (ZWE)

• Nigeria (NGA)

• Thailand (THA)

• Angola (AGO)

• Kenya (KEN)

• China (CHN)

• Viet Nam (VNM)

• DPR Korea (PRK)

• Kazakhstan (KAZ)

• Uzbekistan (UZB)

• Somalia (SOM)

• Peru (PER)

• Kyrgyzstan (KGZ)

• Papua New Guinea (PNG)

• Tajikistan (TJK)

• Belarus (BLR)

• Republic of Moldova (MDA)

• Azerbaijan (AZE)

  1. These are the countries with the largest absolute burden of RR-TB, and that accounted in 2018 for 90% of global RR-TB incidence (Supplementary Fig. 16). The table shows countries grouped into four different categories, for the purpose of modelling. The ISO alpha-3 code for each country is also shown in brackets. We developed a specific model structure for each of the country categories, and calibrated that model separately for each country within each category. Footnotes: (i) We drew these countries from the World Health Organization list of priority countries for public-private-mix programmes46, namely those countries where the private sector plays a strong role in managing TB patients, and which account for the bulk of unreported cases globally. (ii) We identified these countries as those in which HIV coinfection accounted for at least 10% of estimated TB incidence in 2018.
  2. HIV human immunodeficiency virus, RR-TB rifampicin-resistant tuberculosis.
Back to article page